SARS-CoV-2 Therapeutic Landscape, Opportunity and Future Threats

During the past two decades, the world has seen several known and novel zoonotic viruses and deadly bacterial diseases, such as West Nile Virus (1999 to 2002), Anthrax (2001), H1N1(2009), Ebola (2014), Zika Virus (2016), SARS-CoV (2002), MERS-CoV (2012) and SARS-CoV-2 in 2019. The current ongoing COVID-19 pandemic is completely unpredicted and it has hugely changed our health care systems, global economy and social lifestyles. SARS-CoV-2 is still under genetic evolution and getting mutated to escape our immune system and showing resistance against available therapies. In this current research work, we have examined all publicly available scientific literature to date to understand the genetic evaluation of coronavirus species and their transmission possibilities to humans. We have also explored recently reported mutations of concerns in viral spike glycoprotein. We then discussed various SARS-CoV-2 preclinical and clinical research breakthroughs and highlighted our limitations and readiness to combat this deadly disease. Based on our recent study, we have emphasized developing a global viral, fungi and microbes platform. It can help us to predict mutations on their genomic, structural and pathophysiological profile to better address early on future threats by such infectious agents.